Human BioSystems

Human BioSystems

January 06, 2005 07:00 ET

Human BioSystems Awarded Patent For Blood Platelet Preservation


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: HUMAN BIOSYSTEMS

OTC Bulletin Board SYMBOL: HBSC

JANUARY 6, 2005 - 07:00 ET

Human BioSystems Awarded Patent For Blood Platelet
Preservation

PALO ALTO, CALIFORNIA--(CCNMatthews - Jan. 6, 2005) - Human BioSystems
(OTCBB:HBSC) a biomedical research company primarily focused on creating
storage extension solutions for biological materials, announced today it
has been awarded another patent for its blood platelet preservation
technologies.

The patent number US 6,828,090 B2 includes a platelet composition
suitable for direct infusion into patients plus a preservation medium to
extend the current shelf life of blood platelets in a safe and healthy
state.

"This milestone marks the continuing advancements we are making in both
blood platelet and donor organ preservation technologies." Harry Masuda,
President and CEO said. "Our portfolio of awarded patents and patent
pending applications is growing, and we are looking forward to the
granting of other patent applications in both platelet and organ
preservation that are currently in the pipeline."

Human BioSystems is headquartered in Palo Alto, California.

Certain statements contained herein are ``forward-looking'' statements
(as such term is defined in the Private Securities Litigation Reform Act
of 1995). Because such statements include risks and uncertainties,
actual results may differ materially from those expressed or implied by
such forward-looking statements. Factors that could cause results to
differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to, results from
future research and testing, failure to obtain regulatory approval for
the Company's products, if required, failure to develop a product based
on the technology we have acquired, failure of any such products to
compete effectively with existing products, failure to develop a cost
effective commercial manufacturing method, the ability of the Company to
fund additional studies and product development and other factors
discussed in filings made by the Company with the Securities and
Exchange Commission.

-30-

Contact Information